Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Pfeiffer

Showing results (401-410 of 470) with videos related to

Pageof 47
Sort By:
Mutation Research|July 11, 2002
Chromosomal aberrations: formation, identification and distributionG Obe, P Pfeiffer, J R K Savage, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancerC Frederiksen, C Qvortrup, I J Christensen, et al.
The Journal of Biological Chemistry|April 20, 2001
Accurate in vitro end joining of a DNA double strand break with partially cohesive 3'-overhangs and 3'-phosphoglycolate termini: effect of Ku on repair fidelityS Chen, K V Inamdar, P Pfeiffer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2005
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracilP Pfeiffer, H Sørbye, H Ehrsson, et al.
ESMO Open|April 5, 2023
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancerC J A Punt, V Heinemann, T Maughan, et al.
ESMO Open|October 2, 2022
A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancerG Carlsson, A Koumarianou, T K Guren, et al.
Optics Letters|February 16, 2017
Heterogeneous integration of lithium niobate and silicon nitride waveguides for wafer-scale photonic integrated circuits on siliconLin Chang, Martin H P Pfeiffer, Nicolas Volet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative GroupL Bastholt, M Dalmark, S B Gjedde, et al.
Annals of Epidemiology|October 7, 2008
Use of penalized splines in extended Cox-type additive hazard regression to flexibly estimate the effect of time-varying serum uric acid on risk of cancer incidence: a prospective, population-based study in 78,850 menAlexander M Strasak, Stefan Lang, Thomas Kneib, et al.
Wiener Klinische Wochenschrift|November 6, 2009
[Cost of illness and health service patterns in Morbus Parkinson in Austria]Sonja von Campenhausen, Yaroslav Winter, Julia Gasser, et al.
Pageof 47

Showing results (401-410 of 470) with videos related to

Sort By:
Pageof 47
Mutation Research|July 11, 2002
Chromosomal aberrations: formation, identification and distributionG Obe, P Pfeiffer, J R K Savage, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancerC Frederiksen, C Qvortrup, I J Christensen, et al.
The Journal of Biological Chemistry|April 20, 2001
Accurate in vitro end joining of a DNA double strand break with partially cohesive 3'-overhangs and 3'-phosphoglycolate termini: effect of Ku on repair fidelityS Chen, K V Inamdar, P Pfeiffer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2005
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracilP Pfeiffer, H Sørbye, H Ehrsson, et al.
ESMO Open|April 5, 2023
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancerC J A Punt, V Heinemann, T Maughan, et al.
ESMO Open|October 2, 2022
A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancerG Carlsson, A Koumarianou, T K Guren, et al.
Optics Letters|February 16, 2017
Heterogeneous integration of lithium niobate and silicon nitride waveguides for wafer-scale photonic integrated circuits on siliconLin Chang, Martin H P Pfeiffer, Nicolas Volet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative GroupL Bastholt, M Dalmark, S B Gjedde, et al.
Annals of Epidemiology|October 7, 2008
Use of penalized splines in extended Cox-type additive hazard regression to flexibly estimate the effect of time-varying serum uric acid on risk of cancer incidence: a prospective, population-based study in 78,850 menAlexander M Strasak, Stefan Lang, Thomas Kneib, et al.
Wiener Klinische Wochenschrift|November 6, 2009
[Cost of illness and health service patterns in Morbus Parkinson in Austria]Sonja von Campenhausen, Yaroslav Winter, Julia Gasser, et al.
Pageof 47